食管、食管胃交界及胃腺癌中的SMARCA4突变
该研究基于机构数据库,对1174例接受肿瘤二代测序的食管胃癌患者的SMARCA4突变进行分类,并结合组织学与免疫组化分析。42例(3.6%)携带致病性SMARCA4突变,其中71%位于食管或食管胃交界;截短突变多表现为低分化或未分化且常伴免疫组化表达缺失。
要点
- 致病性SMARCA4突变见于3.6%的食管胃癌,以食管及食管胃交界为主。
- 截短SMARCA4突变肿瘤多为低分化或未分化,并常伴SMARCA4免疫组化表达缺失。
- SMARCA4突变肿瘤可伴Barrett食管及APC、CTNNB1共突变。
核心结论
- SMARCA4突变食管胃癌组织学分级呈谱系分布,与Barrett食管相关,共突变模式与野生型腺癌相似。
- SMARCA4缺陷癌虽多呈低分化或未分化,但分子特征提示其与传统食管胃腺癌存在重叠致病通路。
研究设计与样本
- 研究为单机构回顾性数据库分析,纳入接受肿瘤二代测序的食管胃癌患者1174例。
- 对SMARCA4突变进行分类,评估组织学特征,并用免疫组化检测SMARCA4蛋白表达。
主要发现
- 107例(9.1%)检出SMARCA4突变,其中42例(3.6%)为致病性突变。
- 12例截短突变中8例免疫组化SMARCA4表达缺失,7例错义突变均无缺失。
- 4例截短突变癌伴Barrett食管。
关键数值与推荐
- 致病性SMARCA4突变肿瘤中APC突变占31%、CTNNB1突变占14%。
- TP53突变占76%、ARID1A突变占31%,与无致病性SMARCA4突变者频率相近。
- 诊断即转移者中位总生存13.6个月,无转移者22.7个月。
临床怎么用
- 对低分化或未分化的食管胃癌可考虑SMARCA4免疫组化辅助识别SMARCA4缺陷癌。
- 解读SMARCA4突变时应结合变异类型(截短或错义)与蛋白表达结果。
- 伴Barrett食管的食管腺癌中亦需关注SMARCA4突变可能。
局限性
- 研究为单机构回顾性分析,仅纳入接受二代测序的病例,存在选择偏倚可能。
- 免疫组化与突变类型的对应分析样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Deficiency of SMARCA4, a member of the SWI/SNF chromatin remodeling complex, has been described in a subset of undifferentiated gastroesophageal carcinomas with an aggressive clinical course. The full spectrum and frequency of SMARCA4 mutations in gastroesophageal cancer are unknown. We interrogated our institutional database and identified patients with gastroesophageal carcinomas who underwent cancer next-generation sequencing. We classified SMARCA4 mutations, assessed histologic features, and correlated SMARCA4 mutations with SMARCA4 protein expression by immunohistochemistry. SMARCA4 mutations were identified in gastroesophageal carcinomas from 107 (9.1%) of 1174 patients. Forty-nine SMARCA4 mutations, including 26 missense variants and 23 protein-truncating variants, were interpreted as pathogenic in 42 (3.6%) of 1174 patients. Thirty (71%) of 42 cancers with pathogenic SMARCA4 mutations were located in the esophagus or esophagogastric junction, and 12 cancers (29%) were located in the stomach. Sixty-four percent of carcinomas with pathogenic truncating SMARCA4 variants were poorly differentiated or undifferentiated compared with 25% of carcinomas with pathogenic missense variants. Eight of 12 carcinomas with truncating SMARCA4 variants and none of the 7 carcinomas with pathogenic SMARCA4 missense variants showed loss of SMARCA4 expression by immunohistochemistry. Four carcinomas with pathogenic truncating SMARCA4 variants were associated with Barrett esophagus. SMARCA4-mutated gastroesophageal cancers were enriched for APC (31%) and CTNNB1 (14%) mutations and exhibited similar frequency of TP53 (76%) and ARID1A (31%) mutations compared with gastroesophageal cancers without pathogenic SMARCA4 mutations. The median overall survival was 13.6 months for patients who presented with metastasis at diagnosis and 22.7 months for patients without metastasis. Overall, SMARCA4-mutated gastroesophageal cancers exhibit a spectrum of histologic grade, an association with Barrett esophagus, and a concurrent mutational pattern similar to SMARCA4-wild-type gastroesophageal adenocarcinomas. Although SMARCA4-deficient gastroesophageal carcinomas are associated with poorly differentiated and undifferentiated histology, the spectrum of histologic and molecular features suggests overlapping pathogenic pathways with conventional gastroesophageal adenocarcinomas.
引用
- Neil AJ, Zhao L, Isidro RA, et al. SMARCA4 Mutations in Carcinomas of the Esophagus, Esophagogastric Junction, and Stomach. Mod Pathol. 2023. PMID: 37054973. doi:10.1016/j.modpat.2023.100183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。